News Alto Neuroscience, Inc.

Equities

ANRO

US02157Q1094

Market Closed - Nyse Other stock markets 01:30:02 01/06/2024 am IST			5-day change	1st Jan Change
11.96 ^USD	-0.33%		-7.43%	-.--%

21/05	Alto Neuroscience, Inc. Appoints Michael Hanley as Chief Operating Officer	CI
14/05	Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Alto Neuroscience to Present at the Jefferies Global Healthcare Conference	29/05	BU
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer	21/05	BU
Alto Neuroscience, Inc. Appoints Michael Hanley as Chief Operating Officer	21/05	CI
Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights	15/05	BU
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences	09/05	BU
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia	23/04	BU
Alto Neuroscience, Inc. Announces Positive Phase 1 Results for ALTO-101, A Novel PDE4 Inhibitor in Development for Schizophrenia	23/04	CI
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients	03/04	MT
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder	03/04	BU
Alto Neuroscience, Inc. Announces Initiation of Phase 2 Study of Alto-203 in Patients with Major Depressive Disorder	03/04	CI
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights	22/03	BU
Alto Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
Alto Neuroscience, Inc.(NYSE:ANRO) added to S&P TMI Index	18/03	CI
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors	11/03	BU
Alto Neuroscience Appoints Maha Radhakrishnan to Board of Directors	11/03	CI
Alto Neuroscience to Participate in Upcoming Investor Conferences	07/03	BU
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference	27/02	BU
Stifel Initiates Alto Neuroscience With Buy Rating, Price Target is $32	27/02	MT
Baird Initiates Alto Neuroscience With Outperform Rating, Price Target is $32	27/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Alto Neuroscience, Inc.

Equities

ANRO

US02157Q1094

Summary

Filters